TRANSGENE AKTIE | Aktienkurs | Nachrichten | Kurs

DAX	6.340	0,4%	Dow	12.455	-0,6%	Euro	1,2519	-0,2%
ESt50	2.162	0,3%	Nas	2.838	-0,1%	Öl	106,9	0,1%
TDax	752,5	0,1%	Nikkei	8.580	0,2%	Gold	1.573	0,9%

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Depot
Times + Sales	Chart-Analyse	Analysen	Dividende/HV	Profil	Optionsscheine	Watchlist
Börsenplätze	Chartvergleich	Kursziele		Insidertrades	Knock-outs	myHome
Orderbuch	Realtime Stuttgart	RSS Feed	Analyse	im Forum	Fonds	Senden/Drucken
Historisch	Realtime Push	myNews neu		IR-Daten	Anleihen	handeln

Relevant
Alle
vom Unternehmen

Sprache:
Alle
DE
EN

Sortieren:
Datum
meistgelesen

Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.
Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv

17.05.12	Transgene Announces Presentations Relating to TG4010 and JX594/TG6006 at Annual Meeting of the American Society of Clinical Oncology (ASCO) (Businesswire)
09.05.12	Transgene Reports Randomized Phase 2b Data with Its Therapeutic HPV Vaccine TG4001 in Women with CIN2/3 Intraepithelial Cervical Neoplasia (Businesswire)
23.04.12	Transgene Reports Positive Follow Up Phase 2 Data on Its HCV Therapeutic Vaccine TG4040 (Businesswire)
19.04.12	Transgene : First Quarter 2012 Financial Report (Businesswire)
19.04.12	Transgene?s New Therapeutic Vaccine Candidate (TG1050) to Treat Chronic Hepatitis B ("CHB”) Reaches Pre-Clinical Proof of Concept (Businesswire)
20.03.12	Transgene and Jennerex Announce First Patient Treated in Phase 1/2 Clinical Trial of JX594/TG6006 in Combination with Chemotherapy in Patients with Metastatic Colorectal Cancer (Businesswire)
19.03.12	Transgene Reports Full Year 2011 Results (Businesswire)
30.01.12	Transgene Creates a Subsidiary in China and signs Immunocan, a European Commission Subsidized International Scientific Cooperation Program, with Chinese and European Academic Laboratories (Businesswire)

17.05.12	Transgene Announces Presentations Relating to TG4010 and JX594/TG6006 at Annual Meeting of the American Society of Clinical Oncology (ASCO) (Businesswire)
09.05.12	Transgene Reports Randomized Phase 2b Data with Its Therapeutic HPV Vaccine TG4001 in Women with CIN2/3 Intraepithelial Cervical Neoplasia (Businesswire)
23.04.12	Transgene Reports Positive Follow Up Phase 2 Data on Its HCV Therapeutic Vaccine TG4040 (Businesswire)
19.04.12	Transgene : First Quarter 2012 Financial Report (Businesswire)
19.04.12	Transgene?s New Therapeutic Vaccine Candidate (TG1050) to Treat Chronic Hepatitis B ("CHB”) Reaches Pre-Clinical Proof of Concept (Businesswire)
20.03.12	Transgene and Jennerex Announce First Patient Treated in Phase 1/2 Clinical Trial of JX594/TG6006 in Combination with Chemotherapy in Patients with Metastatic Colorectal Cancer (Businesswire)
19.03.12	Transgene Reports Full Year 2011 Results (Businesswire)
30.01.12	Transgene Creates a Subsidiary in China and signs Immunocan, a European Commission Subsidized International Scientific Cooperation Program, with Chinese and European Academic Laboratories (Businesswire)

Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.
Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv

17.05.12	Transgene Announces Presentations Relating to TG4010 and JX594/TG6006 at Annual Meeting of the American Society of Clinical Oncology (ASCO) (Businesswire)
09.05.12	Transgene Reports Randomized Phase 2b Data with Its Therapeutic HPV Vaccine TG4001 in Women with CIN2/3 Intraepithelial Cervical Neoplasia (Businesswire)
23.04.12	Transgene Reports Positive Follow Up Phase 2 Data on Its HCV Therapeutic Vaccine TG4040 (Businesswire)
19.04.12	Transgene : First Quarter 2012 Financial Report (Businesswire)
19.04.12	Transgene?s New Therapeutic Vaccine Candidate (TG1050) to Treat Chronic Hepatitis B ("CHB”) Reaches Pre-Clinical Proof of Concept (Businesswire)
20.03.12	Transgene and Jennerex Announce First Patient Treated in Phase 1/2 Clinical Trial of JX594/TG6006 in Combination with Chemotherapy in Patients with Metastatic Colorectal Cancer (Businesswire)
19.03.12	Transgene Reports Full Year 2011 Results (Businesswire)
30.01.12	Transgene Creates a Subsidiary in China and signs Immunocan, a European Commission Subsidized International Scientific Cooperation Program, with Chinese and European Academic Laboratories (Businesswire)

Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.
Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv

17.05.12	Transgene Announces Presentations Relating to TG4010 and JX594/TG6006 at Annual Meeting of the American Society of Clinical Oncology (ASCO) (Businesswire)
09.05.12	Transgene Reports Randomized Phase 2b Data with Its Therapeutic HPV Vaccine TG4001 in Women with CIN2/3 Intraepithelial Cervical Neoplasia (Businesswire)
23.04.12	Transgene Reports Positive Follow Up Phase 2 Data on Its HCV Therapeutic Vaccine TG4040 (Businesswire)
19.04.12	Transgene : First Quarter 2012 Financial Report (Businesswire)
19.04.12	Transgene?s New Therapeutic Vaccine Candidate (TG1050) to Treat Chronic Hepatitis B ("CHB”) Reaches Pre-Clinical Proof of Concept (Businesswire)
20.03.12	Transgene and Jennerex Announce First Patient Treated in Phase 1/2 Clinical Trial of JX594/TG6006 in Combination with Chemotherapy in Patients with Metastatic Colorectal Cancer (Businesswire)
19.03.12	Transgene Reports Full Year 2011 Results (Businesswire)
30.01.12	Transgene Creates a Subsidiary in China and signs Immunocan, a European Commission Subsidized International Scientific Cooperation Program, with Chinese and European Academic Laboratories (Businesswire)

Keine Nachrichten im Zeitraum eines Monats in dieser Kategorie verfügbar

17.05.12	Transgene Announces Presentations Relating to TG4010 and JX594/TG6006 at Annual Meeting of the American Society of Clinical Oncology (ASCO) (Businesswire)
09.05.12	Transgene Reports Randomized Phase 2b Data with Its Therapeutic HPV Vaccine TG4001 in Women with CIN2/3 Intraepithelial Cervical Neoplasia (Businesswire)

Keine Nachrichten im Zeitraum eines Monats in dieser Kategorie verfügbar

17.05.12	Transgene Announces Presentations Relating to TG4010 and JX594/TG6006 at Annual Meeting of the American Society of Clinical Oncology (ASCO) (Businesswire)
09.05.12	Transgene Reports Randomized Phase 2b Data with Its Therapeutic HPV Vaccine TG4001 in Women with CIN2/3 Intraepithelial Cervical Neoplasia (Businesswire)

17.05.12	Transgene Announces Presentations Relating to TG4010 and JX594/TG6006 at Annual Meeting of the American Society of Clinical Oncology (ASCO) (Businesswire)
09.05.12	Transgene Reports Randomized Phase 2b Data with Its Therapeutic HPV Vaccine TG4001 in Women with CIN2/3 Intraepithelial Cervical Neoplasia (Businesswire)

Keine Nachrichten im Zeitraum eines Monats in dieser Kategorie verfügbar

17.05.12	Transgene Announces Presentations Relating to TG4010 and JX594/TG6006 at Annual Meeting of the American Society of Clinical Oncology (ASCO) (Businesswire)
09.05.12	Transgene Reports Randomized Phase 2b Data with Its Therapeutic HPV Vaccine TG4001 in Women with CIN2/3 Intraepithelial Cervical Neoplasia (Businesswire)

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen
Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen
vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Transgene S.A. zu myNews hinzufügen Was ist das?

Kurszeit	08:01:51	Kursdatum	25.05.2012
Tageshoch	7,42	Eröffnung	7,42
Tagestief	7,42	Vortag	7,49
52 W. Hoch	13,24	Volumen (Stück)	n/a
52 W. Tief	6,93	Marktkapitalisierung (EUR)	235,82 Mio.
52 W. Performance		Börse	FSE

Kurszeit	17:35:00	Kursdatum	25.05.2012
Tageshoch	7,59	Eröffnung	7,41
Tagestief	7,40	Vortag	7,44
52 W. Hoch	13,74	Volumen (Stück)	19.774
52 W. Tief	6,80	Marktkapitalisierung (EUR)	235,82 Mio.
52 W. Performance		Börse	PAR

Marktkapitalisierung in Mio. EUR	235,82
Anzahl Aktien in Mio.	31,70

25.05.2012	7,42
24.05.2012	7,49
23.05.2012	7,41
22.05.2012	7,53	66
21.05.2012	7,47

WKN	913048
ISIN	FR0005175080
Indizes	Nouveau Marché Index

Finanzen.net

Transgene Aktie [WKN: 913048 / ISIN: FR0005175080]

Realtimekurs Transgene S.A. in Euro

Aktienkurs Transgene S.A. in EUR

Aktienkurs Transgene S.A. in EUR

Nachrichten zu Transgene S.A.

Analysen zu Transgene S.A.

Transgene CHART - 1 Jahr - FSE

ANZEIGE

Rating für Transgene:

Transgene Kennzahlen

Transgene Historische Kurse

Zur Aktie Transgene

Zum Unternehmen Transgene

Aktien gleicher Branche mit besserer 1J Perf.

Passende Fonds

Mania Technologie	+456,3%
ARQUANA International PrintMedia	+435,7%
emQtec	+375,0%
CPU Softwarehouse	+363,3%
Windhoff	+354,5%

Land	Frankreich
Branchen	Pharma, Biotech